OTC Watch

All stocks / RDGL

VIVOS INC RDGL

Vivos (RDGL): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQBWashington, USA
Live quote on OTC Markets

Market listing

Full name
VIVOS INC
Market tier
OTCQB
Trading status
Active
Last trade
09:30:12
Website
www.radiogel.com
Source: Stockwatch, 2026-11-17

News headlines

Vivos Inc. Announces Expansion of IsoPet(TM) Animal Cancer Division with Four New Veterinary Clinics Across the United States
2026-11-03 08:30 · News Release
Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel(TM) Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology
2026-09-03 08:00 · News Release
Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet(TM) Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center
2026-08-18 08:30 · News Release
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction
2026-07-27 10:49 · News Release
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update
2026-07-27 08:30 · News Release
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel(TM) Precision Radionuclide Therapy(TM)
2026-07-06 08:30 · News Release
Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet(TM) Manufacturing
2026-06-11 08:30 · News Release
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel(TM) Precision Radionuclide Therapy(TM)
2026-06-05 08:30 · News Release
Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
2026-02-17 08:30 · News Release
Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel(TM) Precision Radionuclide Therapy(TM)
2026-02-10 08:30 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$68,379
Net loss
($3,066,017)
What it means

It spends more than it earns

Under strain

Customers paid it $68,379 in the year. It lost $3.1 million. For every $1 that came in, about $45.84 went out.

The report says
Cash and cash equivalents
$1,558,525
Net cash used in operating activities
($2,057,743)
What it means

The cash could run out soon

Under strain

It had $1.6 million in the bank and used about $171,479 a month. At that pace the money lasts about 9 months unless it borrows or sells more shares.

The report says
Total assets
$1,867,583
Total liabilities
$206,743
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $1.9 million. Its debts and unpaid bills add up to $206,743. That is about $0.11 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-12

Estimated float about 481,555,816 shares as of 2026-11-12: 494,738,110 outstanding minus 13,182,294 held by 2 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-12-31
455.5M
2026-03-30
482.7M
2026-03-31
482.8M
2026-05-14
493.9M
2026-06-30
494.2M
2026-08-12
494.2M
2026-09-30
494.7M
2026-11-12
494.7M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-12 10-Q10-Q
2026-11-09 DEF 14ADEF 14A
2026-11-05 8-K8-K
2026-10-08 8-K8-K
2026-10-08 4
2026-10-05 8-K8-K
2026-10-01 4
2026-09-16 4
2026-08-12 10-Q10-Q
2026-08-10 4
2026-08-10 4
2026-07-22 4

Common questions about RDGL

Does RDGL file reports with the SEC?

Yes. Vivos files with the SEC under company number 0001449349. The most recent filing we hold is a 10-Q dated 2026-11-12.

Source record

How many RDGL shares are outstanding?

494,738,110 shares as of 2026-11-12, as reported to the SEC.

Source record

Has RDGL filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Vivos?

Officers named in its insider filings: Michael K Korenko (CEO) and Brad Allan Weeks (President).

Source record

Is Vivos making money?

Customers paid it $68,379 in the year. It lost $3.1 million. For every $1 that came in, about $45.84 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record